STOP BLOQ: Preventing Fetal Heart Block
This study, called STOP BLOQ, is looking for ways to prevent a serious heart condition in unborn babies called fetal atrioventricular block (AVB). This condition, often linked to mothers with certain antibodies (anti-Ro 52 or 60), can be very dangerous. Researchers believe there might be a short window of time when a less severe form of AVB (2° AVB) can be treated before it becomes irreversible (3° AVB). The study will test two treatments: Dexamethasone, a steroid, and IVIG (intravenous immunoglobulin), which helps the immune system. Success will be measured by how many babies with 2° AVB have a normal heart rhythm at birth. You can join if you are under 18 weeks pregnant and have specific anti-Ro antibodies. The study plans to enroll 1300 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 1300 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed to see if their baby has a normal heart rhythm at birth, measured up to 25 weeks after enrollment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
At a glance
Conditions
Where it's being run
24 sites across 18 statesStudy leadership
- Jill Buyon, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Health
- Bettina Cuneo, MD · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Percentage of 2° AVB subjects with NR (1:1 AV conduction) at birthup to 25 weeks post-enrollment
The presence of NR (normal rhythm) will be determined by electrocardiogram (ECG)